EP0516181A1 - Novel sulfonamide derivatives - Google Patents
Novel sulfonamide derivatives Download PDFInfo
- Publication number
- EP0516181A1 EP0516181A1 EP19920112113 EP92112113A EP0516181A1 EP 0516181 A1 EP0516181 A1 EP 0516181A1 EP 19920112113 EP19920112113 EP 19920112113 EP 92112113 A EP92112113 A EP 92112113A EP 0516181 A1 EP0516181 A1 EP 0516181A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- carbon atom
- general formula
- heptan
- tosylaminobicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940124530 sulfonamide Drugs 0.000 title description 6
- 150000003456 sulfonamides Chemical class 0.000 title description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 39
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 33
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 17
- -1 ciano group Chemical group 0.000 claims abstract description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 14
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 13
- 125000005843 halogen group Chemical group 0.000 claims abstract description 13
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 11
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 11
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 11
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 9
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 8
- 230000000747 cardiac effect Effects 0.000 claims abstract description 7
- 150000003431 steroids Chemical class 0.000 claims abstract description 7
- 206010061216 Infarction Diseases 0.000 claims abstract description 5
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 230000007574 infarction Effects 0.000 claims abstract description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 4
- 206010020772 Hypertension Diseases 0.000 claims abstract description 4
- 208000006011 Stroke Diseases 0.000 claims abstract description 4
- 208000006673 asthma Diseases 0.000 claims abstract description 4
- 230000002490 cerebral effect Effects 0.000 claims abstract description 4
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims abstract description 3
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims abstract description 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims abstract description 3
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 95
- 238000000034 method Methods 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 22
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- ZJMCFPNLQOAANJ-RQOWECAXSA-N (z)-7-[3-[(4-methylphenyl)sulfonylamino]-2-bicyclo[2.2.1]heptanyl]hept-5-enoic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1C(C\C=C/CCCC(O)=O)C2CCC1C2 ZJMCFPNLQOAANJ-RQOWECAXSA-N 0.000 claims 5
- KTIOSGBULVSUAK-RQOWECAXSA-N (z)-7-[3-[(4-methylphenyl)sulfonylamino]-2-bicyclo[2.2.1]heptanyl]hept-5-enamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1C(C\C=C/CCCC(N)=O)C2CCC1C2 KTIOSGBULVSUAK-RQOWECAXSA-N 0.000 claims 1
- YLJPNUKXXQUJBW-XQRVVYSFSA-N (z)-n,n-dimethyl-7-[3-[(4-methylphenyl)sulfonylamino]-2-bicyclo[2.2.1]heptanyl]hept-5-enamide Chemical compound CN(C)C(=O)CCC\C=C/CC1C(C2)CCC2C1NS(=O)(=O)C1=CC=C(C)C=C1 YLJPNUKXXQUJBW-XQRVVYSFSA-N 0.000 claims 1
- ZAEHGVHHDWSNMM-HYXAFXHYSA-N (z)-n-methyl-7-[3-[(4-methylphenyl)sulfonylamino]-2-bicyclo[2.2.1]heptanyl]hept-5-enamide Chemical compound CNC(=O)CCC\C=C/CC1C(C2)CCC2C1NS(=O)(=O)C1=CC=C(C)C=C1 ZAEHGVHHDWSNMM-HYXAFXHYSA-N 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008016 pharmaceutical coating Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 abstract description 22
- 230000003042 antagnostic effect Effects 0.000 abstract description 10
- 230000008602 contraction Effects 0.000 abstract description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 208000019622 heart disease Diseases 0.000 abstract description 2
- 210000001367 artery Anatomy 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 62
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 239000003960 organic solvent Substances 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 230000036772 blood pressure Effects 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 241000700198 Cavia Species 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- OVGWMUWIRHGGJP-WVDJAODQSA-N (z)-7-[(1s,3r,4r,5s)-3-[(e,3r)-3-hydroxyoct-1-enyl]-6-thiabicyclo[3.1.1]heptan-4-yl]hept-5-enoic acid Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@H](O)CCCCC)C[C@@H]2S[C@H]1C2 OVGWMUWIRHGGJP-WVDJAODQSA-N 0.000 description 7
- 101000988961 Escherichia coli Heat-stable enterotoxin A2 Proteins 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 150000003512 tertiary amines Chemical class 0.000 description 6
- ZJMCFPNLQOAANJ-OBFHWUFDSA-N (z)-7-[(1r,2s,3s,4s)-3-[(4-methylphenyl)sulfonylamino]-2-bicyclo[2.2.1]heptanyl]hept-5-enoic acid Chemical compound N([C@H]1[C@@]2([H])CC[C@](C2)([C@@H]1C\C=C/CCCC(O)=O)[H])S(=O)(=O)C1=CC=C(C)C=C1 ZJMCFPNLQOAANJ-OBFHWUFDSA-N 0.000 description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000001270 agonistic effect Effects 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 0 C=*1C*CC1 Chemical compound C=*1C*CC1 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 238000005698 Diels-Alder reaction Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000005694 sulfonylation reaction Methods 0.000 description 3
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- DGRPAZJZBQTEPY-CRWXNKLISA-N (1r,2s,3s,4s)-3-(phenylmethoxycarbonylamino)bicyclo[2.2.1]hept-5-ene-2-carboxylic acid Chemical compound N([C@@H]1[C@H]([C@]2([H])C[C@]1(C=C2)[H])C(O)=O)C(=O)OCC1=CC=CC=C1 DGRPAZJZBQTEPY-CRWXNKLISA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 2
- PICRGRACVLJLOD-VRKREXBASA-N 4-methyl-n-[(1r,2s,3s,4s)-2-(2-oxoethyl)-3-bicyclo[2.2.1]heptanyl]benzenesulfonamide Chemical compound N([C@H]1[C@@]2([H])CC[C@](C2)([C@@H]1CC=O)[H])S(=O)(=O)C1=CC=C(C)C=C1 PICRGRACVLJLOD-VRKREXBASA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XOKSLPVRUOBDEW-UHFFFAOYSA-N pinane Chemical compound CC1CCC2C(C)(C)C1C2 XOKSLPVRUOBDEW-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- XCVAWXXEGFBILF-ARLZBSSXSA-N (1S,2S,3S,4R)-3-(5-methyl-2-propan-2-ylcyclohexyl)oxycarbonylbicyclo[2.2.1]hept-5-ene-2-carboxylic acid Chemical compound C1(CC(C(CC1)C(C)C)OC(=O)[C@H]1[C@H]2C=C[C@@H]([C@@H]1C(=O)O)C2)C XCVAWXXEGFBILF-ARLZBSSXSA-N 0.000 description 1
- NIDNOXCRFUCAKQ-VZFHVOOUSA-N (1s,2s,3s,4r)-bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1[C@]2([H])C=C[C@@]1([H])[C@H](C(O)=O)[C@H]2C(O)=O NIDNOXCRFUCAKQ-VZFHVOOUSA-N 0.000 description 1
- QIKBODFBVIUCGU-SYJOQXSUSA-N (2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R)-4,6-dihydroxy-2-(hydroxymethyl)-5-(methylamino)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CN[C@H]1C(O)O[C@@H]([C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)CO QIKBODFBVIUCGU-SYJOQXSUSA-N 0.000 description 1
- OBSLWIKITOYASJ-WLDMJGECSA-N (3r,4r,5r,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical compound CN[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OBSLWIKITOYASJ-WLDMJGECSA-N 0.000 description 1
- OBSLWIKITOYASJ-RYRJNEICSA-N (3s,4r,5s,6r)-6-(hydroxymethyl)-3-(methylamino)oxane-2,4,5-triol Chemical compound CN[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OBSLWIKITOYASJ-RYRJNEICSA-N 0.000 description 1
- WTCAEVIBYIIUPR-UHFFFAOYSA-M (4-chlorophenoxy)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=CC(Cl)=CC=C1OC[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WTCAEVIBYIIUPR-UHFFFAOYSA-M 0.000 description 1
- KTIOSGBULVSUAK-OBFHWUFDSA-N (Z)-7-[(1R,2S,3S,4S)-3-[(4-methylphenyl)sulfonylamino]-2-bicyclo[2.2.1]heptanyl]hept-5-enamide Chemical compound N([C@H]1[C@@]2([H])CC[C@](C2)([C@@H]1C\C=C/CCCC(N)=O)[H])S(=O)(=O)C1=CC=C(C)C=C1 KTIOSGBULVSUAK-OBFHWUFDSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 125000002992 TXA2 group Chemical group 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- ITBPIKUGMIZTJR-UHFFFAOYSA-N [bis(hydroxymethyl)amino]methanol Chemical compound OCN(CO)CO ITBPIKUGMIZTJR-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- PMAXNHPFNDQMAO-UHFFFAOYSA-N bicyclo[3.1.1]heptan-4-one Chemical compound O=C1CCC2CC1C2 PMAXNHPFNDQMAO-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- HTJZKHLYRXPLLS-VAWYXSNFSA-N bis(5-methyl-2-propan-2-ylcyclohexyl) (e)-but-2-enedioate Chemical compound CC(C)C1CCC(C)CC1OC(=O)\C=C\C(=O)OC1C(C(C)C)CCC(C)C1 HTJZKHLYRXPLLS-VAWYXSNFSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- CHRHZFQUDFAQEQ-UHFFFAOYSA-L calcium;2-hydroxyacetate Chemical compound [Ca+2].OCC([O-])=O.OCC([O-])=O CHRHZFQUDFAQEQ-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- AOMVRYWCXGCVFV-UHFFFAOYSA-N chromium methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OC.[Cr] AOMVRYWCXGCVFV-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- YNLAOSYQHBDIKW-UHFFFAOYSA-M diethylaluminium chloride Chemical compound CC[Al](Cl)CC YNLAOSYQHBDIKW-UHFFFAOYSA-M 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- LNAVMZHVOWXBHU-VRKREXBASA-N ethyl (1r,2s,3s,4s)-3-[(4-methylphenyl)sulfonylamino]bicyclo[2.2.1]heptane-2-carboxylate Chemical compound N([C@@H]1[C@H]([C@]2([H])CC[C@]1(C2)[H])C(=O)OCC)S(=O)(=O)C1=CC=C(C)C=C1 LNAVMZHVOWXBHU-VRKREXBASA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- BDGDWWGTAFXEEW-UHFFFAOYSA-N methylsulfinylmethane;oxalyl dichloride Chemical compound CS(C)=O.ClC(=O)C(Cl)=O BDGDWWGTAFXEEW-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229930006728 pinane Natural products 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- SGUKUZOVHSFKPH-YNNPMVKQSA-N prostaglandin G2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](OO)CCCCC)[C@H]2C\C=C/CCCC(O)=O SGUKUZOVHSFKPH-YNNPMVKQSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- OSWULUXZFOQIRU-UHFFFAOYSA-N tert-butyl 2-aminoacetate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)CN OSWULUXZFOQIRU-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 150000003591 thromboxane A2 derivatives Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
- C07C405/0075—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
- C07C405/0091—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is bridged condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Definitions
- the compounds of the general formula (I), of the present ivnention may be prepared by the step described hereinafter.
- R11' represents an alkyl group of from 1 to 20 carbon atom(s), carbocyclic ring unsubstituted or substituted by an alkyl or alkoxy group of from 1 to 4 carbon atom(s) or halogen atom, or steroid
- R11'' represents an alkyl group of 1 to 8 carbon atom(s) and the other symbols represent the same meaning as described hereinbefore.
- Step 1 is the reaction to form amide bond.
- the reaction may be carried out by reacting (i) with using a corresponding amine shown by the formula H2NR13 (R13 represents the same meaning as described hereinbefore), in an inert organic solvent (methylene chloride, toluene etc), at a temperature of from 0°C to 40°C, after reacting oxalyl chloride, (ii) with using a corresponding amine shown by the formula H2NR13 (R13 represeents the same meaning as described hereinbefore), e.g.
- step [a] is the introduction of a protecting group (trifluoroacetyl group) into an amino group.
- a protecting group trifluoroacetyl group
- it may be carried out with using anhydrous trifluoroacetic acid, in the presence of a tartiary amine (pyridine etc.), in an inert organic solvent (methylene chloride etc.).
- Step [e] is saponification.
- it is carried out (i) with using an aqueous solution of an alkali (sodium hydroxide, potassium carbonate, lithium hydroxide etc.), in a water - soluble organic solvent (tetrahydrofuran, methanol, ethanol etc.), or (ii) with using an alkali described hereinbefore, under the anhydrous condition, in an alkanol (methanol, ethanol etc).
- alkali sodium hydroxide, potassium carbonate, lithium hydroxide etc.
- a water - soluble organic solvent tetrahydrofuran, methanol, ethanol etc.
- an alkali described hereinbefore under the anhydrous condition
- alkanol methanol, ethanol etc.
- Step [m] is hydrolysis. It may be carried out by reacting with using an acid (hydrochloric acid, acetic acid, oxalic acid etc.), in an inert organic solvent (THF, dioxane, lower alkanol etc.), at a temperature of from 50°C to 100°C.
- Optical active compounds of the compounds of the general formula (I), wherein represents a group of the formula (Aa-1), (Aa-3), (Aa-4) or (Aa-6) and which have such a configuration that the upper chain (-CH2-Ba-R1) and the lower chain (-NHSO2-R 2a -R 3a ) bond in trans against the ring with respect to each other, may be prepared as follows: 1,3-cyclopentadiene, 1,3-cyclohexadiene, furan or butadiene are reacted with dimenthyl fumarate or menthylmandelyl fumarate in the presence of Lewis' acid.
- water-soluble salts are preferable.
- the salt can be isolated by freeze-drying the solution, or by filtration if the salt is sufficiently insoluble to the reaction solution, or if necessary, by removing part of the solvent followed by filtration.
Abstract
- (i) COOR¹¹,
- (ii) CH₂OR¹² or
- (iii) CONR¹³R¹⁴,
wherein
R¹¹ represents a carbocyclic ring unsubstituted or substituted by an alkyl or alkoxy group of from 1 to 4 carbon atom(s) or halogen atom, or steroid,
R¹² represents a hydrogen atom or COR¹⁵,
R¹³ and R¹⁴ each represent a hydrogen atom or alkyl group of form 1 to 4 carbon atom(s) or NR¹³R¹⁴ represents an amino acid residue or heterocyclic ring, or
R¹⁵ represents an alkyl group of from 1 to 4 carbon atom(s) or phenyl group,
wherein
represents
Ba represents
- (i) -CH₂-CH₂-(CH₂)m- (Ba-1),
- (ii) cis-CH=CH-(CH₂)m- (Ba-2),
- (iii) -CH₂-O-(CH₂)m- (Ba-3),
- (iV) -S-(CH₂)m- (Ba-4) or
- (V)
R3a represents a carbocyclic or heterocyclic ring unsubstituted or substituted by from one to three of an alkyl group of from 1 to 4 carbon atom(s), alkoxy group of from 1 to 4 carbon atom(s), hydroxy group, carboxyl group, ciano group, halogen atom or nitro group, or
R2a represents an alkyl group of from 1 to 12 carbon atom(s) together with R3a,
cyclodextrin clathrates thereof, or non-toxic salts thereof in case that NR¹³R¹⁴ represents an amino acid residue, possess an antagonistic activity on TXA₂, in particular, inhibit blood platelet aggregation and contraction of artery, and are, therefore, useful for prevention and/or treatment of inflammation, hypertension, thrombus, cerebral apoplexy, asthma, cardiac infarction, angina pectoris, cerebral infarction and death by aucte cardiac diseases in mammales, in particular in humans, which are induced by thromboxane A₂.
Description
- This invention is related to novel sulfonamide derivatives.
- More particularly, this invention is related to
- (1) sulfonamide derivatives of the general formula
- (2) process for the preparation of them and
- (3) treating agent containing them as active ingredient.
- In 1975, Hamberg et al discovered an unstable intermediate in the conversion of prostaglandin G2 into the hemiacetal derivative in platelets [Proc. Nat. Acad. Sci. U.S.A., Vol 72, No.8 page 2994 (1975)]. The intermediates have been named as thromboxane A₂ and its structure has been proposed as follows:
TXA₂ has been found to show various biological activities such as platelet aggregation, aorta contraction and thrombi formation and therefore is considered to be one of the cause by which diseases such as inflammation, thrombus and cardiac infarction are induced. - Some TXA₂ analogues are proposed as compounds having antagonistic activity on TXA₂; for example, compounds which replaced the oxygen atoms on 11a- and 9,11-epoxy-position of TXA₂ by carbon atoms [see Japanese Patent Kokai No. 55-143930], and compounds having pinane skelton [Proc. Nat. Acad. Sci. U.S.A. Vol. 76, No. 6, page 2566 (1979)]. And, the compounds described below which have a cyclopentane skeleton are also known.
- More recently, in the specification of GB No.2184118, the carbocyclic sulfonamide derivatives of the general formula:
(wherein R1C represents a hydrogen atom or lower alkyl group,
R2C represents an alkyl group, substituted or unsubstituted aryl group, aralkyl group or heretocyclic ring,
R3C represents a hydrogen atom or methyl group,
Xc represents a alkylene group or alkenylene group substituted by one or more fluoro atom(s) or, containing one oxygen atom, sulfur atom or phenylene group thereinto,
Yc represents a straight-chain or branched-chain alkylene group or alkenylene group, oxygen atom or sulfur atom,
mc represents an integer of 0 or 1, and
nc represents an integer of 0, 1 or 2.) have been disclosed. And, the following compound was published by Bayer A.G. at 16th International Symposium on the Chemistry of Naitonal Products opened on May 29 - June 3, 1988. - Fig. 1, Fig. 2 and Fig. 3 show the change of rate which the compounds of the present invention inhibit increasing of blood pressure induced by STA₂ in guinea pig at time elapsed.
-
- (i) COOR¹¹,
- (ii) CH₂OR¹² or
- (iii) CONR¹³R¹⁴, wherein
R¹¹ represents a carbocyclic ring unsubstituted or substituted by an alkyl or alkoxy group of from 1 to 4 carbon atom(s) or halogen atom, or steroid,
R¹² represents a hydrogen atom or COR¹⁵,
R¹³ and R¹⁴ each represent a hydrogen atom or alkyl group ofform 1 to 4 carbon atom(s) or
NR¹³R¹⁴ represents an amino acid residue or heterocyclic ring, or
R¹⁵ represents an alkyl group of from 1 to 4 carbon atom(s) or phenyl group, - (i) -CH₂-CH₂-(CH₂)m- (Ba-1),
- (ii) cis-CH=CH-(CH₂)m- (Ba-2),
- (iii) -CH₂-O-(CH₂)m- (Ba-3),
- (iV) -S-(CH₂)m- (Ba-4) or
- (V)
- The terms of alkyl group, alkylene group, alkenylene group and alkoxy group in description each symbol throughout the present specification including claims mean straight-chain or branched-chain alkyl group, alkylene group, alkenylene group and alkoxy group.
- The configuration of double bonds in alkenylene groups are E, Z and E, Z mixtures. Isomers generated by asymmetric carbons existing in case that branched alkyl group are also included.
- The presence of asymmetric centers leads, as is well known, to the existence of isomers. And all each optical isomers and all mixtures thereof are included in the general formula (1). For instance, a mixture of one optical isomer and enantiomer thereof, a racemic body which is an equivalent mixture especially and a mixture of one optical isomer and diastereomer thereof are also included.
-
- In the general formula (I), the ring structures of the formula
are named each and numbered at each position as follows.
As will be apparent to those skilled in the art, ring structures described above have two [in case of the formulae (Aa-4), (Aa-6) and (Aa-7)] or four [in case of the formulae (Aa-1), (Aa-2), (Aa-3), (Aa-5), (Aa-8), (Aa-9), (Aa-10) and (Aa-11)] asymmetric carbon atoms. Namely they are 1-, 2-, 3- and 4- position carbon atoms in the formulae (Aa-1), (Aa-2) and (Aa-3), 2- and 3- position carbon atoms in the formulae (Aa-4), 1 and 2- position carbon atoms in the formulae (Aa-6) and (Aa-7) and 1-, 2-, 3- and 5- position carbon atoms in the formulae (Aa-5), (Aa-8), (Aa-9), (Aa-10) and (Aa-11). - The presence of asymmetric centers leads, as is well known, to the existence of isomers. And all each optical isomers and all mixtures thereof are included in the general formula (I). For instance, a mixture of one optical isomer and enantiomer thereof, a racemic body which is an equivalent mixture especially and a mixture of one optical isomer and diastereomer thereof are also included.
- In the general formula (I) steroids shown by R¹¹ are the compounds which have steroid skeleton substituted by various substituents, for example and preferably cholesterol.
- Carbocyclic ring in the group shown by R¹¹, are mono-, bi- or tri- aromatic carbocylic rings containing not more than 15 carbon atoms which may be partially or fully saturated.
- The rings are, for example, benzene, naphthalene, indene, aqulene, fluorene, phenanthrene, anthracene, acenaphthylene, biphenylene ring and the rings which may be partially or fully saturated thereof. Preferable rings are benzene and cyclohexane. Alkyl groups of from 1 to 4 carbon atom(s) shown by substituents in groups which R¹¹ represent are methyl, ethyl, propyl, butyl and isomeric groups thereof and alkoxy groups of from 1 to 4 carbon atom(s) are methoxy, ethoxy, propoxy, butoxy and isomeric group thereof and halogen atom are fluorine, chlorine, iodine and bromine atom. Preferable substituents in R¹¹ are methyl and isopropyl group. Carbocyclic rings in R¹¹ are also preferable to be unsubstituted.
- In general formula (I), preferable R¹² are hydrogen atom, acetyl and benzoyl gorup.
- In general formula (I), amino acid residues shown by NR¹³R¹⁴ mean α-amino acid residues wherein a hydrogen atom in the amino group is removed.
- For example, they are glycine, alanine, valine, isoleucine, leucine, serin, threonine, proline, asparagine, glutamine, methionine, phenylalanine, tyrosine, aspartic acid, glutamic acid and lysine residue.
- In the general formula (I), heretocyclic rings shown by NR¹³R¹⁴ are mono-, bi- or tri- aromatic heterocyclic rings containing not more than 15 carbon and hetero atoms which may be partially or fully saturated. For example, they are pyrrole, oxazole, imidazole, pyrazole, pyridine, pyrimidine, pyridazine, pyrimidine, pyrazine, pyrroline, pyrrolidine, imidazolidine, pyrrolidine is preferable.
-
- In the general formula (I), out of groups represented by Ba, groups of the formulal (Ba-2) and (Ba-5), having a double bond are prefered. Especially preferable group is a group shown by the formula (Ba-2).
- In the general formula (I), groups shown by the formula -(CH₂)m- represent methylene, ethylene, trimethylene, tetramethylene, pentamethylene and hexamethylene group. Preferable group is a trimethylene group.
- In the general fromula (I), groups shown by R2a represent a bond and an alkylene group of from 1 to 4 carbon atom(s). Preferable group is a bond.
- In the general formula (I), groups shown by R3a represent carbocyclic and heterocyclic rings unsubstituted and substituted by alkyl group of from 1 to 4 carbon atom(s), alkoxy gorup of from 1 to 4 carbon atom(s), nitro group, hydroxy group, carboxyl group, ciano group or halogen atom. Carbocyclic rings described herein are mono-, bi- or tri- aromatic carbocyclic rings containing not more than 15 carbon atoms which may be partially or fully saturated. heterocyclic rings described herein are mono-, bi- or tri- aromatic heterocyclic rings containing not more than 15 carbon and hetero atoms which may be partially or fully saturated. For example they are benzene, naphthalene, pyridine ring. Benzene ring is preferable. Especially preferable R³ is 4-methylphenyl group.
- Alkyl groups of from 1 to 12 carbon atom(s) which R2a and R3a represent together, are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and isomeric groups thereof. All groups are preferable.
- The cyclodextrin clathrates of the compounds shown by the general formula(I), of the present invention may be prepared with using α-, β- or γ- cyclodextrin or a mixture thereof, by the method described in the specification of British Patent Nos. 1,351,238 or 1,419,221.
- By converting into cyclodextrin clathrates, the stability of the compounds of the formula(I) can be increased.
- The compounds in which NR¹³R¹⁴ represents an amino acid among the compounds of the general formula(I), of the present invention may be converted into the corresponding salts. Non-toxic and water-soluble salts are preferable. Suitable salts, for example, are follows:
salts of alkaline metal (sodium, potassium etc.),
salts of alkaline earth metal (calcium, magnesium etc.),
ammonium salts, salts of pharmaceutically acceptable organic amine (tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidineamine, monoethanolamine, diethanolamine, tris(hydroxymethyl)amine, lysine, arginine, N-methyl-D-glucamine etc.). - The compounds of the general formula(I), of the present invention are perfectly novel compounds which have quite different chemical structures from prior known compounds.
- Described concretely,
The compounds in which
represents the formula(A) are carboxylic acid derivatives such as esters with carbocyclic rings and steroids, alcohols and amides with amino acids and heterocyclic ring in the present invention, though the prior compounds inwhich represents the formula(A) are only carboxylic acids and alkyl ester. - Accordingly, the compounds of the present invention are novel compounds having diferent structures from the prior compounds. It can be unexpected that the compounds which have different structures from the prior TXA₂ antagonists as described above, also possess an antagonistic effect against TXA₂.
- Moreover, the compounds of the general formula(I), of this invention possess more useful features in pharmacodynamic effect than the prior TXA₂ antagonists.
- Described concretely, the compounds of the present invention possess an antagonistic activity against TXA₂ and a part of them possess significantly stronger activity than the prior compounds of the formula(b) and(c). And, the inventors have confirmed that some compounds of the present invention hardly possess a side effect i.e. an agonistic activity against TXA₂ (effect of increasing of blood pressure) which the prior TXA₂ antagonists possess. It could be unexpected that the compounds prepared by changing the structures of the prior TXA₂ antagonists as described above possess different activities from the prior TXA₂ antagonists, until the inventors synthesized them and confirmed their activities.
- According to the present invention, the compounds of the general formula (I), of the present ivnention may be prepared by the step described hereinafter.
R¹¹' represents an alkyl group of from 1 to 20 carbon atom(s), carbocyclic ring unsubstituted or substituted by an alkyl or alkoxy group of from 1 to 4 carbon atom(s) or halogen atom, or steroid, R¹¹'' represents an alkyl group of 1 to 8 carbon atom(s) and the other symbols represent the same meaning as described hereinbefore. -
Step 1 is the reaction to form amide bond. For example, the reaction may be carried out by reacting (i) with using a corresponding amine shown by the formula H₂NR¹³ (R¹³ represents the same meaning as described hereinbefore), in an inert organic solvent (methylene chloride, toluene etc), at a temperature of from 0°C to 40°C, after reacting oxalyl chloride, (ii) with using a corresponding amine shown by the formula H₂NR¹³ (R¹³ represeents the same meaning as described hereinbefore), e.g. 2-chloro-1-methylpyridinium iodide and tertiary amine (triethylmaine etc), in an inert organic solvent (methylene chrolide etc), at a temperature of from 0°C to 40°C. In case that an amine shown by the formula HNR¹³R¹⁴ represents an amino acid, the reaction is carried out by reacting the compounds in which a carboxyl group in an amino acid is protected by an appropriate alkyl group, or the compounds in which an amino group having no connection to the reaction is protected by a tert-butoxycarbonyl group (boc group) or a benzyloxy carbonyl group (cbz group), and then hydrolyzing with using an acid (trifluoroacetic acid etc.) or an alkali (sodium hydroxide etc.) to remove a protecting group. -
Step 2 is esterification. For example, it may be carried out by (i) using the corresponding diazoalkane in an inert organic solvent (diethylether, methylene chloride etc) at a temperature of from 0°C to 40°C, (ii) using the corresponding alkylhalide in the presence of a base (sodium carbonate etc.) in an inert organic solvent (acetone, dimethylsulfoxide etc.) at a temperature of from -10°C to 80°C, or (iii) reacting an acid chloride corresponding to the acid of the formula (Ib) and the desired alcohol at a temperature of from -10°C to 40°C. -
Step 3 is reduction. It may be carried out by reacting with using lithium aluminum hydride or diisobutyl aluminum hydride, in an inert organic solvent (tetrahydrofuran, diethylether, lower alkanol etc.), at from -78°C to a room temperature. -
Step 4 is acylation. It may be carried out by reacting an acylhalide or acid anhydride in the presence of a tertiary amine (pyridine, triethylamine) in an inert organic solvent (diethylether, tetrahydrofuran, methylene chloride) or no solvent at a temperature of from -20°C to 50°C. - The compounds of the general formula:
(wherein
represents the formula (A).) in the compounds used as the starting materials, are described in the specification of British Patent Publication No.2184118 and they may be prepared by the following method.
(wherein
represents a group of the fomulae (Aa-1), (Aa-2), (Aa-3), (Aa-4), (Aa-5), (Aa-6) or (Aa-7),
represents a group of the formulae (Aa-1), (Aa-3), (Aa-4), (Aa-6) or (Aa-7),
Ba' represents a group of the formulae (Ba-2) or (Ba-5),
the other symbols represent the same meaning as described hereinbefore, with the proviso that the configurations of two double bond in formula (5) are each E, Z or EZ.). - Explained each reaction steps in detail,
Step 1'-1 is sulfonylation reaction. For example, it may be carried out with using a sulfonyl halide of the formula:
X-SO₂-R2a-R3a (2)
(wherein, X represents a halogen atom and the other symbols represent the same meanings as defined hereinbefore.)
in the presence of Lewis' base (tertiary amine such as triethylamine, pyridine, dimethylaminopyridine etc) as a stimulator, in an inert organic solvent (methylene chloride etc), at a temperature of from -40°C to 50°C (preferably, at from 0°C to room temperature). - Step 1'-2 is saponification. For example, it is carried out with using an aqueous solution of an alkali (sodium hydroxide, potassium carbonate, lithium hydroxide etc.), in a water-soluble organic solvent (tetrahydrofuran, methanol, ethanol etc.) usually at a temperature of from -10°C to 100°C.
- Step 2' is well known reaction as Wittig's reaction. For example, it may be carried out by reacting an aldehyde of the general formula (IV)and a phosphonium salt of the general formula:
(wherein, X¹ and X² each represent a halogen atom and m represents the same meaning as defined hereinbefore)
in the presence of a strong base (potassium tert-butoxide, lithium diisopropylamide, sodium hydride etc), in an inert organic solvent (toluene, tetrahydrofuran, dimethylsulfoxide etc.), at from -78°C to a room temperature. - Step 3' may be carried out by reacting with using methyl benzoate chromium tricarbonyl, as catalyst, in an inert organic solvent (acetone etc.), in an atmosphere of hydrogen, at from 70 to 120 atmospheres, at from 100°C to 150°C.
- Step 4' is reduction reaction. For example, it may be carried out in the presence of hydrogenation catalyst (palladium-carbon, nickel etc), in an alkanol, in an atmosphere of hydrogen, usually at ordinary temperature and pressure or by raising a little the temperature and atmosphere as occasion demands.
- The compounds of the formulae (V), (VI) and (VII) using as starting materials partially include known compounds. New compounds of the present inventional also may be prepared by known method. For example, the compounds of the formula (V) and (VI) wherein represents the formula (Aa-5) may be prepared as follows. And the process of preparation for a part of the compounds shown by the formula (V) was described in the specification of Japanese Patent Kokai No. 61-49, i.e European Patent Publication No. 0171146.
-
- Explained each steps briefly, step [a] is the introduction of a protecting group (trifluoroacetyl group) into an amino group. For example, it may be carried out with using anhydrous trifluoroacetic acid, in the presence of a tartiary amine (pyridine etc.), in an inert organic solvent (methylene chloride etc.).
- Step [b] is elimination reaction of protecting group of hydroxyl group. For example, it may be carried out with using an acid (p-toluene sulfonic acid, acetic acid etc.), in an organic soluvent (methanol-water etc.)
- Step [c] is oxidation. For example, it may be carried out with using an oxidizing agent (oxalyl chloride-dimethylsulfoxide, sulfur trioxide-pyridine complex, dimethylsulfoxide etc), in the presence of a tertiary amine (triethylamine etc.), in a suitable organic solvent (metylene chloride, dimethylsulfoxide etc.).
- Step [d] is wittig's reaction. It may be carried out with using a phosphorane compound of the formula (3) or (4), by the same procedure as described in step 2'.
- Step [e] is saponification. For example, it is carried out (i) with using an aqueous solution of an alkali (sodium hydroxide, potassium carbonate, lithium hydroxide etc.), in a water - soluble organic solvent (tetrahydrofuran, methanol, ethanol etc.), or (ii) with using an alkali described hereinbefore, under the anhydrous condition, in an alkanol (methanol, ethanol etc). These reactions may be carried out usually at a temperature of from -10°C to 100°C.
- Step [f] is sulfonylation reaction. It may be carried out by the same procedure as described step 1'-1.
-
- Explained each steps briefly, step [g] is the reaction to form oxime. It may be carried out by reacting with using a hydroxylamine hydrochloride, in the presence of barium carbonate, in an inert organic solvent (lower alkanol etc.) at from a room temperature to a refluxing temperature.
- Step [h] is inversion. It may be carried out by refluxing with using a base (potassium tert-butoxide etc.), in an inert organic solvent (tetrahydrofuran, lower alkanol etc.).
- Step [i] may be carried out by reducing the compound of the formula (13) with using Raney Nickel as catalyst, or refluxing with using metallic sodium in an lower alkanol (propanol etc.).
- The compund of the formula (12-1) may be prepared with using β-pinene, α-pinene and 2-oxonorpinane as starting material by the same process as described in the specification of Japanese Patent Kokai No. 61-49.
- The compounds of the fomula (V), (VI) and (VII) wherein
represents the groups of the formula (Aa-1), (Aa-3), (Aa-4), (Aa-6) and (Aa-7) may be prepared, for example, as follows. In scheme, R⁵' represents a phenyl group substituted or unsubstituted, or lower alkyl group. The other symbols represent the same meaning as defined hereinbefore. - Explained each steps briefly, step [j] is reduction. It may be carried out with using lithium aluminum hydride or diisobutyl aluminum hydride, in an inert organic solvent (tetrahydrofuran, diethylether, lower alkanol etc.), at from -78°C to a room temperature.
- Step [k] is oxidation. It may be carried out by the same procedure as step [c] described hereinbefore.
-
- Step [m] is hydrolysis. It may be carried out by reacting with using an acid (hydrochloric acid, acetic acid, oxalic acid etc.), in an inert organic solvent (THF, dioxane, lower alkanol etc.), at a temperature of from 50°C to 100°C.
- Step [n] may be carried out by the same procedure as from step [d] to [e].
- Step [o] is elimination of a benzyloxycarbonyl group. It may be carried out by the same reduction as
step 4 described hereinbefore. - Step [p] is sulfonylation. It may be carried out by the same procedure as
step 1 described hereinbefore. -
- The compound of the formula (14) may be prepared as follows.
Explained each steps briefly, step [r] may be carried out by reacting with using an ethyl chloroformate, in the presence of a tertiary amine (triethylamine etc.), in an inert organic solvent (acetone etc.), at from -10°C to a room temperature, then adding sodium azide and reacting at the same temperature as above. - Step [s] may be carried out by refluxing the compound of the formula (28) in an inert organic solvent (toluene etc.) to obtain the corresponding isocyanate and then reacting it and benzyl alcohol in the presence of a tertiary amine (triethylamine etc.) or an acid (p-toluenesulfonic acid etc.).
- The compound of the formula (27) used as starting material may be prepared by
- (1) refluxing the corresponding acid anhydride in ethanol,
- (2) hydrolyzing the corresponding diethyl ester by one equivalent of alkali or
- (3) hydrolyzing the corresponding diethyl ester with using a hydrolytic enzyme.
- Acid anhydrides and diethyl esters corresponding to the compound of the formula (27) are known as (±) bodies or may be prepared easily from known dicarboxylic acids.
- If desired, (±) bodies may be resolved into each optically active compounds. The optical resolution may be carried out by the known method [See Tables of resolving agents and optical resolutions, University of Hotre dame press (1972) etc.] in a preferable step, for example, step of the compound (27).
- Optical active compounds of the compounds of the general formula (I), wherein
represents a group of the formula (Aa-1), (Aa-3), (Aa-4) or (Aa-6) and which have such a configuration that the upper chain (-CH₂-Ba-R¹) and the lower chain (-NHSO₂-R2a-R3a) bond in trans against the ring with respect to each other, may be prepared as follows: 1,3-cyclopentadiene, 1,3-cyclohexadiene, furan or butadiene are reacted with dimenthyl fumarate or menthylmandelyl fumarate in the presence of Lewis' acid. The optically active Diels-Alder adduct thus obtained may be converted into a monomenthylester carboxylic acid or the other monoalkylester carboxylic acid, corresponding to the compound of the formula (27) to subject subsequent reactions. On this occasion, a double bond in the Diels - Alder adduct must be reduced in a suitable step [for example, the Diels-Alder adduct or the compound of the fomrula (19)]. - Each starting materials and reagents, used in the present invention are known per se or may be prepared by methods known per se.
- Throughout the specification, in each reactions, products may be purified by conventional methods, for example, distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate or washing or recrystallization. Purification may be carried out after each reactions or a series of reactions.
- The cyclodextrin clathrates of carbocyclic sulfonamide derivatives shown by the general formula (I) may be prepared with using α-, β- or γ- cyclodextrin or a mixture thereof, by the method described in the specification of Japanese Patent Kokoku Nos. 50-3362 or 52-31404 and British Patent No. 1351238 and U.S. Patnet No. 3816393.
- The stabilities of the compounds shown by the general formula (I) are enlarged by converting them into cyclodextrin clathrates.
- The acid of the general formula (I) wherein NR¹³R¹⁴ represents an amino acid residue, are converted into salts by known methods.
- The salts are preferably non-toxic ones. The non-toxic salts herein referred mean salts of cations such that it is relatively innoxious to living body (animals including humans) tissues and that the effective pharmacological properties of the compound(s) of the general formula (I) are not impaired by side effect(s) resulting from the cations when used in an amount required for the treatment.
- And water-soluble salts are preferable.
- Suitable salts include, for example, a salt of an alkali metal (sodium, potassium etc.), a salt of an alkaline earth metal (calcium, magnesium etc.), an ammonium salt and a pharmaceutically acceptable (non-toxic) amine salt.
- Amines suitable for forming such salts with carboxylic acid are well known, and include, for example, those amines which are theoretically obtained by substituting one or more of hydrogen atom(s) of ammonia by other groups.
- Examples of such amine are, an amino acid (arginine, lysine, glutamine, histidine, asparagine etc), a sugar-amine (N-methylglucane, N-methylmannosamine, N-methylgalactosamine, N-methylfructosamine, N-methylarabinosamine, N-methylribosamine, N-methyllactosamine etc.) and another amine (ethanolamine, triethanolamine, triethylamine, meglumine, guanidine etc.).
- The salt can be obtained by known method par se, for example, by reacting an acid of the general formula (I) wherein NR¹³R¹⁴ represents an amino acid residue, with a suitable base (e.g. a hydroxide or carbonate of an alkali metal or an alkaline earth metal, ammonia or an amine) in theoretical amounts in an appropriate solvent.
- The salt can be isolated by freeze-drying the solution, or by filtration if the salt is sufficiently insoluble to the reaction solution, or if necessary, by removing part of the solvent followed by filtration.
- The compounds of the general formula (I), of the present invention, possess an antagonistic action against thromboxane A₂, especially inhibitory effect on platelet aggregation, on contraction of smooth muscle or on increasing of blood pressure.
- For example, in standard laboratory test, the effects were possible to be confirmed by (i) inhibitory effect on contraction of smooth muscle induced by STA₂ in guinea pigs or (ii) inhibitory effect on increasing of blood pressure induced by STA₂ in guinea pigs (intravenously and orally).
- The results of the experiments carried out are shown in the following table I.
- The methods for the experiments hereinbefore described are detailed as follows.
- Inhibitory effect on increasing of blood pressure induced by STA₂ in guinea pigs: A 7% sodium bicarbonate buffer solution (pH 7.6 ∼ 8.6) of each tested compounds was administered intravenously via carotid vein or orally to a urethane-anaesthetized male guinea pig weighing 250 ∼ 350 g, at a rate of 10 - 1000 µg/kg animal body weight. And then guinea pigs were administered intravenously a solution of STA₂ in phosphate buffer (pH 7.4). Change of the blood pressure was measured at carotid artery and then inhibition ratio (%) was calculated.
- Of the compounds of the general formula (I) of the present invention, some compounds have an antagonistic effect on thromboxane A₂, especially inhibitory effect on increasing of blood pressure, lasting for a long time, and have a weak agonistic effect on thromboxane A₂ (stimulatory effect on increasing of blood pressure).
- For example, in standard laboratory test, the effects were possible to be confirmed by (i) inhibitory effect on increasing of blood pressure induced by STA₂ in guinea pigs (antagonistic effect) and (ii) stimulatory effect on increasing of blood pressure in guinea pigs (agonistic effect).
-
- The methods for the experiments described in Table I and Figure 1 and 2 are detailed as follows.
- Inhibitory effect on increasing of blood pressure induced by TXA₂ in guinea pigs and stimulatory effect on increasing of blood pressure in guinea pigs: A 7% sodium bicarbonate buffer solution (pH 7.6 ∼ 8.6) of each tested compounds was administered intravenously via carotid vein or orally to a urethane-anaesthetized male guinea pig weighing 250 ∼ 350 g, at a rate of 100 µg/kg animal body weight. Increasing of blood pressure was measured in guinea pigs administered test compounds intravenously. On the other hand, to guinea pigs administered test compounds orally, then a solution of STA₂ in phosphate buffer (pH 7.4) was administered. Change of the blood pressure was measured at carotid artery and then inhibition ratio (%) was calculated.
- The foregoing results show that the compounds of the present invention possess an antagonistic effect on TXA₂. Some of them have an antagonistic effect on TXA₂, especially inhibitory effect on increasing of blood pressure, lasting for longer time than the compared compounds, and have a weak agonistic effect on TXA₂, i.e. stimulatory effect on increasing of blood pressure.
- The compounds of the present invention, of the general formula (I), cyclodextrin clathrates thereof and non-toxic salts thereof have an antagonistic effect on TXA₂ such as an inhibitory effect on platelet aggregation, on contraction of smooth muscle or on increasing of blood pressure, and are, therefore, useful for prevention and/or treatment of inflammation, hypertension, thrombus, cerebral apoplexy, asthma, cardiac infarction, angina pectoris, cerebral infarction and death by acute cardiac disorders in mammals, in particular in human, which are considred to be inudced by thromboxane A₂.
- For the purpose hereinbefore described, the compounds of the present invention, of the general formula (I), cyclodextrin clathrates thereof and non-toxic salts thereof may normally be administered systemically or partially; usually by oral or parenteral administration. The doses to be administered is determined depending upon age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment etc. In the human adult, the doses per person per dose are generally between 1 mg and 5 g, by oral administration up to several times per day, and between 10 µg and 1 g, by parenteral administration up to several times per day. As mentioned above, the doses to be used depend upon various conditions. therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.
- Solid compositions according to the present invention for oral administration include compressed tablets, dispersible powders and granules. In such solid compositions, one or more of the active compound(s) is or are, admixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, startch, polyvinylpyrrolidone or magnesium metasilicate aluminate. The compositions may also comprise, as is normal practice, additional sustances other than inert diluents e.g. lubricating agents such as magnesium stearate, disintegrating agents such as cellulose calcium glycolate, stabilizing agent e.g. lactose and assistant for dissolving e.g. arginine, glutamic acid or aspartic acid. The tablets or pills may, if desired, be made into gastric film-coated or enteric film-coated tablets or pills, such as sugar-coated, gelatin-coated, hydroxypropyl cellulose-coated or hydroxypropylmethyl cellulose phthalate-coated tablets or pills; two or more of layers may be used. The compositions for oral administration also include capsules of absorbable material such as gelatin.
- Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as distilled water or ethanol. Besides inert diluents such compositions may also comprise adjuvants such as wetting and suspending agents, and sweetening, flavouring, perfuming and presserving agents.
- Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s).
- Preparations for injection according to the present invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions or emulsions. Example of aqueous solvents or suspending media are distilled water for injection and physiological salt solution. Examples of non-aqueous solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, POLYSORBATE 80 (registered Trade Mark). These compositions may also include adjuvants such as preserving, wetting, emulsifying, despersing agents, stabilizing agents (e.g. lactose) and assistant agent for dissolving (e.g. arginine, glutamic acid or aspartic acid). They may also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
- Other compositions for parenteral administration include liquids for external use, and endermic liniments such as ointments, suppositories for rectal administration and pessaries for vaginal administration whcih comprise one or more of the active compound(s) and may be prepared by known methods.
- The following reference examples and examples illustrate the present invention, but not limit the present invention.
- In the reference examples and examples, "bp", "mp", "TLC", "NMR", "IR" and "MS" represent "boiling point", "melting point", "Thin layer chromatography", "Nuclear magnetic reasonance spectrum", "Infrared absorption spectrum" and "Mass spectrum", respectively.
- The solvents in the parentheses show the developing or eluting solvents and the rations of the solvents used are by volume in chromatographic separations.
- Unless otherwise specified, "NMR" was measured in a chloroform-d (CDC1₃) solution and "IR" was measured by the liquid film method respectively.
-
-
-
- Di-(-)-menthyl fumarate (3.82g) dissolved in toluene (100 ml) was cooled to -78°C. Diethylaluminum chloride (1.49g) was added dropwise to the mixture. The mixture was stirred for 30 minutes. 1,3-cyclopentadiene (660mg) distilled freshly was added to the obtained reaction solution. The mixture was stirred for 30 minutes at a temperature of -78°C and then the temperature of the solution was raised to -20°C by degrees. 2N hydrochloric acid (200 ml) was added to the reaction mixture. The organic layer was separated. The water layer was extracted twice with ether. The extract was washed with water, dried over sodium sulfate and then evaporated to obtain the title compound (4.2g) having the following physical data:
NMR(CCl₄ solution): δ 6.20 (2H, S), 4.60 (2H, m), 3.40 (2H, m), 2.55 (2H, m). - The mixture of
2N aqueous solution of sodium hydroxide (1mℓ) was added to dimenthyl ester (1.0g, prepared in reference example 1 ) dissolved in ethanol (20mℓ). The mixture was refluxed for 30 minutes. The reaction mixture was evaporated. Water (50mℓ) was added to the residue. The mixture was extracted with ethyl acetate. The water layer was acidified by adding 1N hydrochloric acid. The mixture was extracted with ethyl acetate. The extract was washed with water, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (ethyl acetate: n-hexane=2:3) to obtain the title compound (320mg) having the following physical data:
NMR (CCl₄ solution): δ 6.17 (2H), 4.36 (2H), 3.5 ∼ 2.5 (4H, m). - The mixture of
Triethylamine (120mg) was added to the half ester (320mg, prepared in reference example 2 ) dissolved in acetone (5mℓ). The solution was cooled to 0°C. Ethyl chloroformate (130mg) was added dropwise to the solution. The mixture was stirred for 20 minutes. Sodium azide (130mg) dissolved in water (1mℓ) was added to the mixture cooled to 0°C. The mixture was stirred with keeping a same temperature for 30 minutes. The water was added to the reaction mixture. The mixture was extracted three times with toluene to obtain a toluene solution of the corresponding 3-azidecarbonyl body. The solution was dried over magnesium sulfate and then refluxed for 2 hours to obtain the corresponding 3-isocyanate. Benzylalcohol (108mg) and a catalyst amount of tributylamine were added to the obtained reaction mixture. The mixture was refluxed for 3 hours. The reaction mixture was evaporated. The residue was purified by column chromatography on silica gel (ethyl acetate: n-hexane=1:6) to obtain the title compound (mixture, 340mg) having the following physical data.
NMR: δ 7.2 (5H), 6.3 (2H), 4.95 (2H, S), 4.35 (2H, m), 2.95 (2H, m). -
- Two isomers obtained in reference example 3 were purified by column chromatography on silica gel (ethyl acetate: n-hexane=3:7) to obtain the title two compounds having the following physical data.
- (a) (1R, 2S, 3S, 4S) isomer:
TLC (methylene chloride: n-hexane: ether=12:4:1) : Rf=0.35. - (b) (1S, 2S, 3S, 4R) isomer:
TLC (methylene chloride: n-hexane: ether=12:4:1) : Rf=0.32. -
- 12N hydrochloric acid (0.41mℓ) and palladium-carbon (content: 10%, 200mg) were added to 2-menthyloxycarbonyl-3-benzyloxycarbonylamino compound (prepared in reference example 4 (a), 1.08g) dissolved in anhydrous ethanol (10mℓ). The mixture was stirred in an atmosphere of hydrogen, at a room temperature, for 2 hours. The catalyst was removed from the mixture by filtration. The filtrate was evaporated to obtain hydrochloric acid salt of the corresponding amine. The obtained amine was dissolved in pyridine (10mℓ). Tosyl chloride (1.24g) and triethylamine (0.45mℓ) were added to the mixture with cooling in an ice-bath. The mixture was stirred at a room temperature for 12 hours. The yellow-orange reaction mixture was poured into 4N hydrochloric acid (50mℓ). The mixture was extracted with ethyl acetate (100mℓ). The extract was washed with a saturated aqueous solution of sodium bicarbonate, followed by a brine, dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (ethyl acetate: n-hexane=1:2) to obtain [(1R, 2S, 3S, 4S)-3-tosylaminobicyclo [2.2.1] heptan-2-yl]carboxylic acid ethyl ester.
- Next, in an atmosphere of argon, the ethyl ester obtained before (860mg) dissolved in anhydrous THF (5mℓ) was added dropwise to lithium aluminum hydride (LAH, 186mg) suspended in anhydrous tetrahydrofuran (THF, 15mℓ) at a room temperature. The mixture was stirred for 30 mins. The reaction mixture was cooled to 0°C. The mixture of THF-water (5:2) was added to the mixture to quench excess LAH. The occurred mixture such as rice gruel was dissolved by adding 1N hydrochloric acid (30mℓ). The mixture was extracted three times with ethyl acetate (20mℓ). The extract was dried over magnesium sulfate and then evaporated to obtain the corresponding alcohol (white solid, 683mg).
- Next, alcohol described above (309mg) was dissolved in dimethyl sulfoxide (DMSO, 5mℓ). Triethylamine (0.5mℓ) was added to the solution. Trioxide-pyridine complex (477mg) dissolved in DMSO (2mℓ) was added dropwise to the solution. The mixture was stirred at a room temperature for 1 hour, poured into ice-water (30mℓ) and extracted twice with ethyl acetate (20mℓ). The extract was dried over magnesium sulfate and then evaporated.
- The obtained residue was purified by column chromatography on silica gel (ethyl acetate: methylene chloride=1:10) to obtain [(1R, 2S, 3S, 4S)-3-tosyl aminobicyclo [2.2.1] heptan-2-yl] aldehyde (287mg, white solid).
- Next, 1.4 M solution (2.1mℓ) of n-butyllithium in hexane was added dropwise to diisopropylamine (0.5mℓ) dissolved in tetrahydrofuran (THF, 3mℓ) at a temperature of 0°C. The mixture was stirred for 15 minutes to obtained a solution of lithiumdiisopropylamide (LDA).
- Next, a solution of LDA prepared before was added dropwise to 4-chlorophenoxymethyl-triphenylphosphoniumchloride (1.32g) suspended in THF (10mℓ) at a temperature of 0°C to obtain a deep red solution.
- Aldehyde (287mg) prepared before dissolved in THF (5mℓ) was added dropwise to the solution. The solution was stirred at a temperature of 0°C for 30 minutes. The reaction mixture was poured into ice-water (30mℓ). The mixture was extracted twice with ethyl acetate (50mℓ). The extract was dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (ethyl acetate: n-hexane=1:3) to remove polar substances. Enol ether obtained before was concentrated 1.4- dioxane (10ml) and 4N hydrochloric acid (2ml) were added to the residue The mixture was stirred at 80°C for 40 minutes. Ice cooled 10% aqueous solution of sodium hydroxide (30ml) was added to the mixture. The mixture was extracted twice with ethyl acetate (50ml). The extract was dried over magnesium sulfate and evaporated to obtaine the title compound having the following physical data. The compound was used in next step without purification.
NMR: δ 9.75 (1H, bs), 7.75 (2H, d), 7.30 (2H, d);
MS: m/e 307 (M⁺), 289, 278. -
- Potassium tert-butoxide (740mg) was added to 4-carboxybutyltriphenylphosphoniumbromide (1.33g) suspended in toluene (10mℓ). The mixture was stirred at a temperature of 80°C for 40 minutes. The obtained reaction solution was cooled to 0°C. [(1R, 2S, 3S, 4S)-3-tosylaminobicyclo [2.2.1] heptan-2-yl]acetoaldehyde (270mg; prepared in reference example 5 ) dissolved in toluene (3mℓ) was added dropwise to the solution. The solution was stirred at a temperature of 0°C for 15 minutes. The reaction mixture was poured into ice-water. The mixture was extracted three times with ether (20mℓ) to remove neutral substances and basic substances. The water layer was acidified with 1N hydrochloric acid (10mℓ). The solution was extracted twice with ethyl acetate (30mℓ). The extract was dried over magnesium sulfate and evaporated. The residue was purified by column chromatography on silica gel (methylene chloride: methanol=100:1→25:1) to obtain the title compound (222mg) having the following physical data:
TLC (methylene chloride: methanol=10:1): Rf 0.45;
NMR: δ 7.75 (2H, d), 7.28 (2H, d), 5.26 (2H, m), 5.11 (1H, d), 3.00 (1H, broad), 2.42 (3H, S), 2.37 (2H, t), 2.16∼0.87 (15H);
MS: m/e 391 (M⁺), 373;
m.p.: 77∼78°C;
feature: white crystal. -
- Oxalyl chloride (2mℓ) was added to (5Z)-7-[(1R, 2S, 3S, 4S)-3-tosylaminobicyclo [2.2.1] heptan-2-yl]hep-5-tenoic acid (100mg, prepared in reference example 6). The mixture was stirred at a room temperature for 1 hour. Excess oxalyl chloride was removed from the mixture in vacuo to obtain an acid chloride. This acid chloride was dissolved in methylene chloride (5mℓ). The solution was cooled to 0°C and became turbid by blowing ammonia gas through the solution. The mixture was stirred at a room temperature for 30 mins. The insoluble substance was removed by filtration. The filtrate was concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate: hexane=1:1→5:1) to obtain the title compound 81.4 mg having the following physical data:
TLC (ethyl acetate: hexane=5:1) : Rf 0.35;
NMR: δ 7.76 (2H, d), 7.27 (2H, d), 5.80 (1H, broad), 5.62 (1H, broad), 5.61 (1H, d), 5.33 (2H, m), 3.04 (1H, broad), 2.43 (3H, S);
MS: m/e 390 (M⁺), 332, 290, 278, 235, 218;
feature: colorless wax. -
-
- (5Z)-7-[(1R, 2S, 3S, 4S)-3-tosylaminobicyclo [2.2.1] heptan-2-yl]hept-5-enoic acid (100mg, prepared in reference example 6.), glycine tert-butyl ester hydrochloride (65.3mg), 2-chloro-1-methylpyridinium iodide (100mg) and triethylamine (0.22mℓ) were dissolved in methylene chloride (5mℓ). The mixture was stirred at a room temperature for 4 hours. The solvent was removed. The residue was purified by column chromatography on silica gel (ethyl acetate: hexane=1:2) to obtain the condensed compound. Methylene chloride (2mℓ) and trifluoroacetic acid (1mℓ) were added to the compound. The solution was stirred overnight and then concentrated. Trifluoroacetic acid was removed by boiling with toluene. The residue was purified by column chromatography on silica gel (methanol: methylene chloride=1:10) to obtain the title compound (56mg) having the following physical data: TLC (methanol: methylene chloride=1:10): Rf 0.10;
NMR: δ 7.72 (2H, d), 7.31 (2H, d), 6.30 (1H, t), 6.08 (1H, d), 5.30 (2H, m), 4.20 (1H, dd), 3.95 (1H, dd), 2.84 (1H, d), 2.43 (3H, s);
MS: m/e 448 (M⁺), 332, 307, 293, 277, 265;
feature: colorless amorphous. -
-
- Oxalyl chloride (2mℓ) was added to (5Z)-7-[(1R, 2S, 3S, 4S)-3-tosylaminobicyclo [2.2.1] heptan-2-yl]hept-5-enoic acid (100mg, prepared in reference example 6 ). The mixture was stirred at a room temperature for 1 hour. Excess oxalyl chloride was removed in vacuo to obtain an acid chloride.
- Next, tetrahydrofuran (4mℓ) and 4N aqueous solution of sodium hydroxide (1mℓ) were added to ε-t-butylcarbonyl-L-lysine (492mℓ). The solution was cooled to 0°C. Acid chloride prepared before dissolved in anhydrous tetrahydrofuran (2mℓ) was added dropwise to the solution. The reaction solution was stirred enough for 20 mins, acidified with 1N hydrochloric acid and then extracted with ethyl acetate. The ethyl acetate layer was dried over magnesium sulfate, filtrated and concentrated. The residue was purified by column chromatography on silica gel (methanol: methylene chloride=1:20→1:10) to obtain the condensed compound. The obtained condensed compound was dissolved in methylene chloride (2mℓ). Trifluoroacetic acid (1mℓ) was added to the solution. The mixture was stirred at a room temperature for 3 hours. The solvent was removed by evaporation. The residue was purified by column chromatography on silica gel (methanol: methylene chloride = 1:10→1:5→2:3) to obtain the title compound (97.4mg) having the following physical data.
TLC (methanol: methylene chloride = 2:3): Rf=0.20;
NMR: δ 7.73 (2H, d), 7.31 (2H, d), 5.23 (2H, m), 2.91 (4H, m), 2.43 (3H, s);
MS: m/e 501 (M-18), 346, 218;
feature: pale yellow amorrhous.
wherein
represents
Ba represents
R3a represents a carbocyclic or heterocyclic ring unsubstituted or substituted by from one to three of an alkyl group of from 1 to 4 carbon atom(s), alkoxy group of from 1 to 4 carbon atom(s), hydroxy group, carboxyl group, ciano group, halogen atom or nitro group, or
R2a represents an alkyl group of from 1 to 12 carbon atom(s) together with R3a;
cyclodextrin clathrates thereof, or non-toxic salts thereof in case that NR¹³R¹⁴ represents an amino acid residue, process for the preparation of them, and treating agent containing them as active ingredient.
Claims (6)
- A sulfonamide derivative of the general formula:(i) COOR¹¹,(ii) CH₂OR¹² or(iii) CONR¹³R¹⁴,
wherein
R¹¹ represents a carbocyclic ring unsubstituted or substituted by an alkyl or alkoxy group of from 1 to 4 carbon atom(s) or halogen atom, or steroid,
R¹² represents a hydrogen atom or COR¹⁵,
R¹³ and R¹⁴ each represent a hydrogen atom or alkyl group of form 1 to 4 carbon atom(s) or NR¹³R¹⁴ represents an amino acid residue or heterocyclic ring, or
R¹⁵ represents an alkyl group of from 1 to 4 carbon atom(s) or phenyl group,(i) -CH₂-CH₂-(CH₂)m- (Ba-1),(ii) cis-CH=CH-(CH₂)m- (Ba-2),(iii) -CH₂-O-(CH₂)m- (Ba-3),(iV) -S-(CH₂)m- (Ba-4) or(V)R2a represents a bond or an alkylene group of from 1 to 4 carbon atom(s),
R3a represents a carbocyclic or heterocyclic ring unsubstituted or substituted by from one to three of an alkyl group of from 1 to 4 carbon atom(s), alkoxy group of from 1 to 4 carbon atom(s), hydroxy group, carboxyl group, ciano group, halogen atom or nitro group, or
R2a represents an alkyl group of from 1 to 12 carbon atom(s) together with R3a,
cyclodextrin clathrates thereof, or non-toxic salts thereof in case that NR¹³R¹⁴ represents an amino acid residue. - A derivative according to claim 2, which is
(5Z)-7-(3-tosylaminobicyclo[2.2.1]heptan-2-yl)hept-5-enamide,
(5Z)-N-methyl-7-(3-tosylaminobicyclo[2.2.1]heptan-2-yl)hept-5-enamide,
(5Z)-N,N-dimethyl-7-(3-tosylaminobicyclo[2.2.1]heptan-2-yl)hept-5-enamide,
amide of (5Z)-7-(3-tosylaminobicyclo[2.2.1]heptan-2-yl)hept-5-enoic acid and pyrrolidine,
amide of (5Z)-7-(3-tosylaminobicyclo[2.2.1]heptan-2-yl)hept-5-enoic acid and glycine,
amide of (5Z)-7-(3-tosylaminobicyclo[2.2.1]heptan-2-yl)hept-5-enoic acid and alanine,
amide of (5Z)-7-(3-tosylaminobicyclo[2.2.1]heptan-2-yl)hept-5-enoic acid and glutamic acid or
amide of (5Z)-7-(3-tosylaminobicyclo[2.2.1]heptan-2-yl)hept-5-enoic acid and lysine. - A process for the preparation of the compounds of the general formula:
which is characterized by
subjecting the compound of the general formula:
subjecting the compound of the general formula:
to esterification,
subjecting the compound of the the general formula:
to reduction,
subjecting the compound of the general formula:
to acylation - A pharmaceutical composition for the prevention and/or treatment of hypertension, thrombus, cerebral apoplexy, asthma, cardiac infarction, angina pectoris, cerebral infarction, and acute cardiac deseases, which comprises, as active ingredient, an effective amount of at least one compound of the general formula ( I ) depicted in claim 1 wherein various symbols are as defined in claim 1, or a cyclodextrin clathrate thereof, or, when
NR¹³R¹⁴ represents an amino acid residue, a non-toxic salt thereof, together with a pharmaceutical carrier or coating. - A compound as claimed in claim 1, a cyclodextrin clathrate thereof, or when NR¹³R¹⁴ represents a non-toxic salt thereof, for use in manufacture of a medicament for the prevention and/or treatment of hypertension, thrombus, cerebral apoplexy, asthma, cardiac infarction, angina pectoris, cerebral infarction, and acute cardiac deseases.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26650187 | 1987-10-23 | ||
JP266501/87 | 1987-10-23 | ||
JP197180/88 | 1988-08-09 | ||
JP63197180A JP2565746B2 (en) | 1987-10-23 | 1988-08-09 | New carbocyclic sulfonamide derivative |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88116960.1 Division | 1988-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0516181A1 true EP0516181A1 (en) | 1992-12-02 |
Family
ID=26510214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19920112113 Withdrawn EP0516181A1 (en) | 1987-10-23 | 1988-10-12 | Novel sulfonamide derivatives |
Country Status (1)
Country | Link |
---|---|
EP (1) | EP0516181A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2039480A (en) * | 1979-01-05 | 1980-08-13 | Jones R | Prostaglandins |
EP0226346A1 (en) * | 1985-11-18 | 1987-06-24 | Shionogi & Co., Ltd. | Bicyclic sulfonamide derivatives |
-
1988
- 1988-10-12 EP EP19920112113 patent/EP0516181A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2039480A (en) * | 1979-01-05 | 1980-08-13 | Jones R | Prostaglandins |
EP0226346A1 (en) * | 1985-11-18 | 1987-06-24 | Shionogi & Co., Ltd. | Bicyclic sulfonamide derivatives |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0608847B1 (en) | Carbocyclic sulfonamides as agonists or antagonists of PGEZ | |
Beerthuis et al. | Biologically active prostaglandins from some new odd‐numbered essential fatty acids | |
US5168101A (en) | Sulfonamide derivatives | |
CA1264320A (en) | Prostaglandin analogues, process for their preparation and pharmaceutical compositions containing them | |
US6235777B1 (en) | Benzenesulfonamide compounds | |
EP0122019B1 (en) | A prostaglandin analogue | |
EP0044711B1 (en) | 9,11-methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof | |
CA2040319C (en) | Sulfonylamino substituted bicyclyl hydroxamic acid derivatives | |
HU199411B (en) | Process for producing cyclopentyl ether derivatives and pharmaceutical compositions containing them as active components | |
EP0171146B1 (en) | 13-aza-14-oxo-txa2 analogues | |
EP0516181A1 (en) | Novel sulfonamide derivatives | |
HU193708B (en) | Process for preparing the furyl derivatives of 16-substituted prostaglandines | |
EP0107693A1 (en) | 2,3,4-trinor-1,5-inter-m-phenylene-prostacyclin-i2 analogues, process for the preparation thereof and pharmaceutical compositions containing the same. | |
EP0578847B1 (en) | Fused benzeneoxyacetic acid derivatives and their use as PG12 antagonists | |
JP2565746B2 (en) | New carbocyclic sulfonamide derivative | |
US5164412A (en) | 5-hetero-6-oxo-pge-derivatives | |
EP0516180A1 (en) | Novel sulfonamide derivatives | |
JPS62277352A (en) | Novel 6-keto-prostaglandin e1 derivative, production thereof and remedy for cytopathy containing said derivative as active component | |
US3847962A (en) | Prostaglandins and process and intermediates therefor | |
JP2913157B2 (en) | New carbocyclic sulfonamide derivatives | |
JPH07588B2 (en) | Polyenoic acid derivative | |
SE431090B (en) | OPTICAL ACTIVE OR RACEMIC FLUOR-PROSTAGLAND INCORPORATION FOR USE AS A LUTEOLYTIC AND ABORTIVE AGENT | |
JP3140999B2 (en) | Benzenesulfonamide compounds, methods for their preparation and prostaglandin E2 receptor antagonists containing them as active ingredients | |
CS236890B2 (en) | Processing of 5-fluorine -3-oxo-6-carbaprostaglandine i2 derivatives | |
JPH0723336B2 (en) | Carbacyclin derivative and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 312906 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MIYAZAKI, TOHRU, DAI 2 MINASE HAITSU 501 Inventor name: HAMANAKA, NOBUYUKI Inventor name: ARAI, YOSHINOBU |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19921031 |